Physician Assistant Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Cindy Hunter

Physician Assistant, Medical Shreveport, LA Physician Assistant

NPI 1669960886 CMS profile 11541043

7591 Fern Ave Ste 1705, Shreveport, LA 71105

Open in the dashboard

General payments

$4,528

215 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cindy Hunter of Shreveport, LA is reported in the CMS Open Payments database as having received $4,528 across 215 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 87th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,124 115
2024 General $1,836 86
2023 General $568 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cindy Hunter
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Cindy Hunter were reported at $2,124. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Cindy Hunter Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $0 $156 $41–$563 $132
2022 $0 $185 $55–$649 $149
2023 $568 $199 $58–$717 $160
2024 $1,836 $206 $62–$740 $164
2025 $2,124 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Alkermes, Inc. $783 45 payments
  2. Neurocrine Biosciences, Inc. $660 38 payments
  3. Teva Pharmaceuticals USA, Inc. $517 18 payments
  4. ITI, Inc. $309 12 payments
  5. Axsome Therapeutics, Inc. $306 6 payments
  6. E.R. Squibb & Sons, L.L.C. $300 13 payments
  7. Corium, Inc. $265 13 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $245 16 payments
  9. Janssen Pharmaceuticals, Inc $200 10 payments
  10. AbbVie, Inc. $187 5 payments
  11. Other $755 39 payments

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $4,515 213 payments
  2. Education $13 2 payments
Products named General payments · program years 2023–2025
  1. LYBALVI Cns $783 45 payments
  2. INGREZZA $660 38 payments
  3. ARISTADA Cns $488 41 payments
  4. ARISTADA Cns $488 41 payments
  5. ARISTADA Cns $488 41 payments
  6. ARISTADA Cns $488 41 payments
  7. Austedo XR $392 17 payments
  8. Auvelity $306 6 payments
  9. LYBALVI Cns $295 4 payments
  10. LYBALVI Cns $295 4 payments
  11. Other $2,685 113 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

187

Median for Physician Assistant: 241

Drug cost

$3,170

Median for Physician Assistant: $4,110

Branded share of claims

0%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Lurasidone Hcl Generic 22 $1,743
Hydroxyzine Hcl Generic 20 $296
Trazodone Hcl Generic 21 $264
Buspirone Hcl Generic 14 $235
Mirtazapine Generic 11 $139
Risperidone Generic 21 $128
Duloxetine Hcl Generic 12 $128
Amitriptyline Hcl Generic 15 $111
Quetiapine Fumarate Generic 18 $60
Clonazepam Generic 19 $46

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 18 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
  • Teva Pharmaceuticals USA, Inc. $246
$246 — —
INGREZZA
  • Neurocrine Biosciences, Inc. $169
$169 — —
Auvelity
  • Axsome Therapeutics, Inc. $167
$167 — —
Azstarys
  • Corium, Inc. $158
$158 — —
REXULTI
  • Otsuka America Pharmaceutical, Inc. $77
  • Lundbeck LLC $74
$151 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 18 in the dashboard with a free account

Records

215 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record